Menu
Search
|

Menu

Close
X

Diffusion Pharmaceuticals Inc DFFN.OQ (NASDAQ Stock Exchange Capital Market)

0.33 USD
-0.02 (-4.43%)
As of 3:14 PM EST
chart
Previous Close 0.34
Open 0.36
Volume 13,015
3m Avg Volume 30,273
Today’s High 0.36
Today’s Low 0.31
52 Week High 2.08
52 Week Low 0.31
Shares Outstanding (mil) 50.57
Market Capitalization (mil) 16.72
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.329
FY17
-0.862
FY16
-1.768
FY15
-2.515
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
--
22.95
Price to Book (MRQ)
vs sector
0.61
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-1.74
13.00
Return on Equity (TTM)
vs sector
-77.92
14.69

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2020 Avon Ct Ste 4
CHARLOTTESVILLE   VA   22902-8734

Phone: +1434.2200718

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

SPONSORED STORIES